Pulmonary Computed Tomography Screening Frequency in Primary Antibody Deficiency
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Patients with primary antibody deficiency (PAD) frequently suffer from pulmonary complications, associated with severe morbidity and mortality. Hence, regular pulmonary screening by computed tomography (CT) scanning is advised. However, predictive risk factors for pulmonary morbidity are lacking.
OBJECTIVE: To identify patients with PAD at risk for pulmonary complications necessitating regular CT screening.
METHODS: A retrospective, longitudinal cohort study of patients with PAD (median follow-up 7.4 [2.3-14.8] years) was performed. CTs were scored using the modified Brody-II scoring system. Clinical and laboratory parameters were retrospectively collected. Potential risk factors were identified by univariate analysis when P < .2 and confirmed by multivariable logistic regression when P < .05.
RESULTS: The following independent risk factors for progression of airway disease (AD) were identified: (1) diagnosis of X-linked agammaglobulinemia (XLA), (2) recurrent airway infections (2.5/year), and (3) the presence of AD at baseline. Signs of AD progression were detected in 5 of 11 patients with XLA and in 17 of 80 of the other patients with PAD. Of the 22 patients who progressed, 17 had pre-existent AD scores ≥7.0%. Increased AD scores were related to poorer forced expiratory volume in 1 second values and chronic cough. Common variable immunodeficiency and increased CD4 effector/memory cells were risk factors for an interstitial lung disease (ILD) score ≥13.0%. ILD ≥13.0% occurred in 12 of 80 patients. Signs of ILD progression were detected in 8 of 80 patients, and 4 of 8 patients showing progression had pre-existent ILD scores ≥13.0%.
CONCLUSION: We identified risk factors that distinguished patients with PAD at risk for AD and ILD presence and progression, which could guide future screening frequency; however, independent and preferably prospective validation is needed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. In practice - 12(2024), 4 vom: 09. Apr., Seite 1037-1048.e3 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Smits, Bas M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Airway disease |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaip.2023.12.047 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366727087 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366727087 | ||
| 003 | DE-627 | ||
| 005 | 20240409232323.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaip.2023.12.047 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM366727087 | ||
| 035 | |a (NLM)38182096 | ||
| 035 | |a (PII)S2213-2198(24)00004-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Smits, Bas M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pulmonary Computed Tomography Screening Frequency in Primary Antibody Deficiency |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Patients with primary antibody deficiency (PAD) frequently suffer from pulmonary complications, associated with severe morbidity and mortality. Hence, regular pulmonary screening by computed tomography (CT) scanning is advised. However, predictive risk factors for pulmonary morbidity are lacking | ||
| 520 | |a OBJECTIVE: To identify patients with PAD at risk for pulmonary complications necessitating regular CT screening | ||
| 520 | |a METHODS: A retrospective, longitudinal cohort study of patients with PAD (median follow-up 7.4 [2.3-14.8] years) was performed. CTs were scored using the modified Brody-II scoring system. Clinical and laboratory parameters were retrospectively collected. Potential risk factors were identified by univariate analysis when P < .2 and confirmed by multivariable logistic regression when P < .05 | ||
| 520 | |a RESULTS: The following independent risk factors for progression of airway disease (AD) were identified: (1) diagnosis of X-linked agammaglobulinemia (XLA), (2) recurrent airway infections (2.5/year), and (3) the presence of AD at baseline. Signs of AD progression were detected in 5 of 11 patients with XLA and in 17 of 80 of the other patients with PAD. Of the 22 patients who progressed, 17 had pre-existent AD scores ≥7.0%. Increased AD scores were related to poorer forced expiratory volume in 1 second values and chronic cough. Common variable immunodeficiency and increased CD4 effector/memory cells were risk factors for an interstitial lung disease (ILD) score ≥13.0%. ILD ≥13.0% occurred in 12 of 80 patients. Signs of ILD progression were detected in 8 of 80 patients, and 4 of 8 patients showing progression had pre-existent ILD scores ≥13.0% | ||
| 520 | |a CONCLUSION: We identified risk factors that distinguished patients with PAD at risk for AD and ILD presence and progression, which could guide future screening frequency; however, independent and preferably prospective validation is needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Airway disease | |
| 650 | 4 | |a Brody II score | |
| 650 | 4 | |a CVID | |
| 650 | 4 | |a GLILD | |
| 650 | 4 | |a Primary antibody deficiency | |
| 650 | 4 | |a Risk factor | |
| 700 | 1 | |a Boland, Sharisa L |e verfasserin |4 aut | |
| 700 | 1 | |a Hol, Marjolein E |e verfasserin |4 aut | |
| 700 | 1 | |a Dandis, Rana |e verfasserin |4 aut | |
| 700 | 1 | |a Leavis, Helen L |e verfasserin |4 aut | |
| 700 | 1 | |a de Jong, Pim A |e verfasserin |4 aut | |
| 700 | 1 | |a Prevaes, Sabine M P J |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamed Hoesein, Firdaus A A |e verfasserin |4 aut | |
| 700 | 1 | |a van Montfrans, Joris M |e verfasserin |4 aut | |
| 700 | 1 | |a Ellerbroek, Pauline M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. In practice |d 2013 |g 12(2024), 4 vom: 09. Apr., Seite 1037-1048.e3 |w (DE-627)NLM227247523 |x 2213-2201 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:4 |g day:09 |g month:04 |g pages:1037-1048.e3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaip.2023.12.047 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 4 |b 09 |c 04 |h 1037-1048.e3 | ||